$7.39
2.38% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US04335A1051
Symbol
ARVN
Sector
Industry

Arvinas, Inc. Stock price

$7.39
+1.10 17.49% 1M
-12.11 62.10% 6M
-11.78 61.45% YTD
-19.06 72.06% 1Y
-23.51 76.08% 5Y
-8.66 53.96% 10Y
-8.66 53.96% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.18 2.38%
ISIN
US04335A1051
Symbol
ARVN
Sector
Industry

Key metrics

Market capitalization $539.41m
Enterprise Value $-414.39m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.64
EV/Sales (TTM) EV/Sales -0.97
P/S ratio (TTM) P/S ratio 1.26
P/B ratio (TTM) P/B ratio 0.82
Revenue growth (TTM) Revenue growth 121.31%
Revenue (TTM) Revenue $426.90m
EBIT (operating result TTM) EBIT $-95.60m
Free Cash Flow (TTM) Free Cash Flow $-252.80m
Cash position $954.30m
EPS (TTM) EPS $-0.66
P/E forward negative
P/S forward 1.88
EV/Sales forward negative
Short interest 10.76%
Show more

Is Arvinas, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Arvinas, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Arvinas, Inc. forecast:

12x Buy
57%
9x Hold
43%

Analyst Opinions

21 Analysts have issued a Arvinas, Inc. forecast:

Buy
57%
Hold
43%

Financial data from Arvinas, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
427 427
121% 121%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 168 168
3% 3%
39%
- Research and Development Expense 355 355
46% 46%
83%
-92 -92
85% 85%
-21%
- Depreciation and Amortization 4.10 4.10
15% 15%
1%
EBIT (Operating Income) EBIT -96 -96
85% 85%
-22%
Net Profit -47 -47
92% 92%
-11%

In millions USD.

Don't miss a Thing! We will send you all news about Arvinas, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arvinas, Inc. Stock News

Neutral
GlobeNewsWire
one day ago
– ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (also known as AITL) and transformed follicular lymphoma –
Neutral
GlobeNewsWire
8 days ago
– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine –
Neutral
GlobeNewsWire
9 days ago
– Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (AITL) and transformed follicular lymphoma, and in combination with small molecule inhibitors in models of diffuse large B-cell lymphoma –
More Arvinas, Inc. News

Company Profile

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.

Head office United States
CEO John Houston
Employees 430
Founded 2013
Website www.arvinas.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today